
SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF SOME NEW PYRAZOLES INCORPORATED WITH IMIDAZOLE, PYRROLE AND OTHER CYCLIC AND HETEROCYCLIC MOIETIES.

TALAAAT I. EL-EMARY^A, ABU-BAKR A. A. M. EL-ADASY^{*B} AND MOHAMED A. M. GAD-ELKAREEM^B

^a *Department of Chemistry, Faculty of Science, Assiut University, Assiut 71516 Egypt. Current Address: Al-Jouf Teachers College, P.O. Box 269, Al-Jouf, Skaka, Saudi Arabia.*

^b *Department of Chemistry, Faculty of Science, Al-Azhar University at Assiut, Assiut 71524 Egypt.*

** a_eladasy@yahoo.com*

Abstract:

Condensation of 1,3-diphenylpyrazole-4-carboxaldehyde (**1**) with some cyclic and heterocyclic active methylene derivatives afforded the condensation products **2-5**. The reaction of **1** with benzoylglycine afforded the key intermediate 4-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-2-phenyl-1,3-oxazol-5(4*H*)-one (**6**). Also, **1** reacted with malononitrile to give **7**. The later reacted with 1*H*-indene-1,3(2*H*)-dione to give **9**. The oxazolone **6** reacted with some aromatic and heteroaromatic amine derivatives to yield 5-[(1*H*-pyrazol-4-yl)methylene]-3,5-dihydro-4*H*-imidazol-4-one derivatives **11a,b**, **12**, **13** and **15**. Reacting the oxazolone **6** with acetylacetone, ethyl acetoacetate, 5,5-dimethylcyclohexane-1,3-dione and 1*H*-indane-1,3-(2*H*)-dione gave the 1*H*-pyrazol-4-ylmethylenepyrrolidine-2,4-dione, 1*H*-pyrazol-4-ylmethylenepyrrrol-3-one, 1*H*-pyrazol-4-ylmethyleneindole-3,4-dione and 1*H*-pyrazol-4-ylmethyleneindeno[1,2-*b*]pyrrole-3,4-dione derivatives **18-21** respectively. Antibacterial activity of some of the newly synthesized compounds was studied.

Keywords: 1,3-Diphenylpyrazole, oxazolone, pyrrolone, imidazolone, indanedione and antibacterial.


Introduction

In the recent years a lot of attention on the synthesis and chemistry of pyrazoles has been reported¹⁻⁶ because of their significant and versatile biological and pharmacological activities, such as anti-leishmanial⁷, antimalarial⁸, analgesic and anti-inflammatory⁹, photo-antiproliferative¹⁰, antibacterial and antifungal¹¹⁻¹⁵, as potent cannabinoid CB1 receptor antagonists^{16,17}. Has potential glucocorticoid receptor ligand for positron emission tomography (PET)¹⁸. As well, have good properties as anticancer¹⁹ and antiparasitic^{20,21}. Recently, imidazoles were used as Potent anticytokine agents with low activity against hepatic cytochrome P450

enzymes²², antithrombotics²³, cardioprotective²⁴, antibacterial²⁵, agents and kinase inhibitors²⁶. Moreover, pyrroles were used as antiviral²⁷, antiepileptic²⁸, anticoccidial²⁹, antibacterial³⁰ agents and histone deacetylase inhibitors³¹. In continuation to our previous work directed towards the synthesis and reactions of substituted pyrazoles^{1,2,6,13-15,20,32} and imidazoles³³⁻³⁵, we report, here, a new and convenient method for the synthesis and antibacterial activities of some new pyrazole incorporated with imidazole, pyrrole and other cyclic and heterocyclic moieties utilizing 1,3-diphenyl-1*H*-pyrazole-4-carboxaldehyde.

Results And Discussion


Condensation of 1,3-diphenylpyrazole-4-carboxaldehyde (**1**)³⁶ with some cyclic active methylene compounds such as cyclohexanone, 5,5-dimethylcyclohexane-1,3-dione, 1*H*-indene-1,3(2*H*)-dione and 3-methyl-2,4-dihydro-3*H*-pyrazol-5-one yielded the condensation products 2-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]cyclohexanone (**2**), 2-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-5,5-dimethylcyclohexane-1,3-dione (**3**), 2-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-1*H*-indane-1,3(2*H*)-dione (**4**) and 4-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-5-methyl-2,4-dihydro-3*H*-pyrazol-3-one (**5**) respectively (Scheme 1).



Scheme 1


Reaction of **1** with benzoylglycine in acetic acid /acetic anhydride in presence of fused sodium acetate under reflux afforded 4-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-2-phenyl-1,3-oxazol-5(4*H*)-one (**6**). The IR spectrum of **6** indicated the presence of C=O at $\nu = 1790\text{ cm}^{-1}$, and its ^1H NMR revealed $\delta = 7.02$ (s, 1H, ethylenic-H), 7.42-7.95 (m, 15H, Ar-H) and 9.10 (s, 1H, pyrazole-H) (Scheme 1).

Condensing **1** with malononitrile gave [(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]malononitrile (**7**)¹⁴. Reacting **7** with 1*H*-indane-1,3(2*H*)-dione in DMF containing equivalent amount of KOH afforded 4-(1,3-diphenyl-1*H*-pyrazol-4-yl)-2,5-dioxo-2,5-dihydro-1*H*-indeno[1,2-*b*]pyridine-3-carbonitrile (**9**). The structure of compound **9** was confirmed by elemental analysis and spectral data. Its IR spectrum indicated the presence of NH at $\nu = 3386\text{ cm}^{-1}$, CN at $\nu = 2223\text{ cm}^{-1}$ and two C=O at $\nu = 1722, 1679\text{ cm}^{-1}$, and its ^1H NMR revealed 7.37-8.00 (m, 14H, Ar-H), 9.05 (s, 1H, pyrazole-H) and 10.07 (s, 1H, NH). The formation of **9** is assumed to proceed *via* the intermediate **8**, which underwent Dimorth rearrangement³⁷ under the applied reaction condition to give **9** (Scheme 2).



Scheme 2

The oxazolone **6** was used as key intermediate for the synthesis of the some imidazole derivatives *via* its reaction with some aromatic and heteroaromatic amines. Thus, **6** reacted with 2-aminophenol (**10a**) in glacial acetic acid solution in presence of fused sodium acetate to produce 5-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-3-(2-hydroxyphenyl)-2-phenyl-3,5-dihydro-4*H*-imidazol-4-one (**11a**). The IR spectrum of **11a** indicated the presence of OH at $\nu = 3350\text{ cm}^{-1}$ and C=O at $\nu = 1653\text{ cm}^{-1}$, while its ^1H NMR revealed $\delta = 7.10$ (s, 1H, ethylenic-H), 7.25-7.97 (m, 19H, Ar-H), 9.40 (s, 1H, pyrazole-H) and 10.01 (s, 1H, OH) (Scheme 3).



Scheme 3


Similarly **6** reacted with 2-aminobenzoic acid (**10b**) and p-phenylenediamine to give 2-{4-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methyl-ene]-5-oxo-2-phenyl-4,5-dihydro-1*H*-imidazol-1-yl}benzoic acid (**11b**) and 3-(4-aminophenyl)-5-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-2-phenyl-3,5-dihydro-4*H*-imidazol-4-one (**12**) respectively (Scheme 3).

As well, **6** reacted with some heteroaromatic amines as 3-aminopyridine and 5-amino-4-cyano-2-methyl-*N*-(4-methyl-phenyl)thiophene-3-carboxamide (**14**) to yield 5-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-2-phenyl-3-pyridin-3-yl-3,5-dihydro-4*H*-imidazol-4-one (**13**) and 4-cyano-5-{4-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-5-oxo-2-phenyl-4,5-dihydro-1*H*-imidazol-1-yl}-*N*-(4-methyl-phenyl)-2-methylthiophene-3-carboxamide (**15**) respectively (Scheme 3).

The strategy has also extended to synthesis new pyrrolones moieties attached to 1,3-diphenylpyrazole nucleuses at position -4. Thus, on reacting the oxazolone **6**

with acetylacetone in dioxan in presence of sodium metal³⁸, it afforded 4-acetyl-2-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-5-methyl-1,2-dihydro-3*H*-pyrrol-3-one (**18**). The IR spectrum of **18** indicated the presence of NH at $\nu = 3279 \text{ cm}^{-1}$ and two C=O at $\nu = 1702, 1643 \text{ cm}^{-1}$, and its ¹H NMR revealed $\delta = 2.05$ (s, 3H, COCH₃), 3.22 (s, 3H, CH₃), 7.32 (s, 1H, ethylenic-H), 7.38-8.01 (m, 10H, aromatic-H), 8.72 (s, 1H, pyrazole-H) and 10.00 (s, 1H, NH) (Scheme 4). The formation of **18** is assumed to take place *via* the corresponding nonisolable intermediate **16**, which readily cyclizes under the reaction conditions to give **17**. The latter compound undergoes debenzoylation³⁸ to give the final product **18** (Scheme 4).

Finally, **6** reacted with: ethyl acetoacetate, 5,5-dimethylcyclohexane-1,3-dione and 1*H* indane-1,3(2*H*)-dione to achieved 3-acetyl-5-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]pyrrolidine-2,4-dione (**19**), 6,6-dimethyl-2-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-6,7-dihydro-1*H*-indole-3,4(2*H*, 5*H*)-dione (**20**) and 2-[(1,3-diphenyl-1*H*-pyrazol-4-yl)methylene]-1,2-dihydro-indeno[1,2-*b*]pyrrole-3,4-dione (**21**) respectively. The structure of compounds **18-21** was established based on elemental analyses, spectral data and literature³⁸ reports (Scheme 4).



Scheme 4

Antibacterial Activity

Ten of the synthesized compounds were screened *in vitro* for their antibacterial activities against three strains of bacteria (*Escherichia Coli*, *Pseudomonas areuginosa* and *Klebsiella pneumonia*) using the filter paper disc technique³⁹. The results are given in Table III. The screened compounds were dissolved in DMF to get a solution of 1% concentration. Filtered paper discs (Whatman No. 1 filter paper, 5 mm diameter) were saturated with this solution. The discs were placed on the surface solidified nutrient agar dishes seeded by the tested bacteria. Inhibition zones were measured at the end of an incubation period of 48 h. (at 37 °C). Tioconazole (Tyrosyd) was used as reference substance. Most compounds showed from moderate to strong activities against *klebsiella* Pneumonia. Compounds **4**, **18**, **19** and **21** showed strong activities against *Pseudomonas areuginosa*. Compounds **6**, **11a**, **15**, **19** and **21** showed from weak to moderate activities against *Escherichia coli*. The rest of the compounds exhibited nil activities against all strains of bacteria used.

Exepremental

Melting points were measured with a Gallenkamp apparatus and are uncorrected. IR spectra in KBr discs were recorded on BRUKER Vector 22 FT-IR spectrophotometer. ¹H NMR spectra were determined in DMSO-*d*₆ at 300 MHz on Varian Mercury VX spectrometer using TMS as an internal standard. Chemical shifts are expressed as δ ppm. Elemental analyses were carried out at the Microanalytical Center of Cairo University. Mass spectra were recorded on a Finnigan Mat SSQ-7000 apparatus at 70 eV. Compounds **1**³⁶ and **7**¹⁴ were prepared according to the literature procedures.

Condensation of 1 with cyclic active methylene compounds:

General procedure

A mixture of **1** (0.01 mol) and cyclic active methylene compounds namely: cyclohexanone, 5,5-dimethyl-cyclohexane-1,3-dione, 1*H*-indene-1,3(2*H*)-dione and 5-methyl-2,4-di-hydro-3*H*-pyrazol-3-one (0.01 mol) in ethanol (30 mL) and catalytic amount of triethyl amine (0.5 mL) was heated under reflux for 3 h. The solid precipitate that formed was collected, dried and recrystallized from the proper solvents to give **2-5** respectively (Tables I and II).

*Reaction of 1 with benzoylglycine: Formation of 4-((1,3-diphenyl-1*H*-pyrazol-4-yl)methylene)-2-phenyl-1,3-oxazol-5(4*H*)-one (6).*

A mixture of **1** (0.01 mol), benzoylglycine (0.01 mol) and fused sodium acetate (0.03 mol) in acetic acid (10 mL) and acetic anhydride (10 mL) was heated on a

steam bath for 3 h. The reaction mixture was then poured into a cold mixture of ethanol-water (1:1) (50 ml) and stirred for 15 min. The solid precipitate that formed was collected, washed with cold ethanol, dried and recrystallized from acetic acid to give **6** (Tables I and II).

Reaction of 7 with 1H-indane-1,3(2H)-dione. Formation of 4-(1,3-diphenyl-1H-pyrazol-4-yl)-2,5-dioxo-2,5-dihydro-1H-indeno[1,2-b]pyridine-3-carbonitrile (9).

A mixture of compound **7** (0.01 mol) and 1H-indane-1,3(2H)-dione (0.01 mol) in DMF (30 mL) containing 0.01 mol KOH was heated under reflux for 5 h. The reaction mixture was cooled, poured onto ice-water and neutralized with dil. HCl. The solid product that formed was filtered off, dried and crystallized from dioxan to give **9** (Tables I and II).

Reaction of 6 with aromatic and hetero-aromatic amines: Formation of 11a, 11b, 12, 13 and 15.

General procedure

A mixture of **6** (0.01 mol) and aromatic or hetero-aromatic amines namely: 2-aminophenol (**10a**), 2-aminobenzoic acid (**10b**), 3-aminopyridine, p-phenylenediamine and 5-amino-4-cyano-2-methyl-N-(4-methylphenyl) thio-phenyl-3-carboxamide (**14**) (0.01 mol) and fused sodium acetate (0.03 mol) in glacial acetic acid (30 mL) was heated under reflux for 1 h., then cooled. The reaction mixture was poured onto cold water. The solid products were filtered off, washed with water, dried and recrystallized from the proper solvents to give **11a, 11b, 12, 13** and **15** respectively (Tables I and II).

Reaction of 6 with: acetylacetone, ethyl acetoacetate, 5,5-dimethyl-cyclohexane-1,3-dione and 1H-indene-1,3(2H)-dione: Formation of compounds 18- 21.

General procedure

A finely divided sodium metal (0.01 mol) was added to a solution of the appropriate active methylene compounds (0.01 mol) in dioxan (30 mL) and the mixture was stirred at room temperature for 24 h., after that compound **6** (0.01 mol) was added. The reaction mixtures were heated under reflux for 8 h. The reaction mixtures were then poured onto ice-cold water and acidified with dilute HCl. The solid products that formed were collected, washed with water, dried and crystallized from the proper solvent to give **18 – 21** (Table I and II).

Acknowledgment

The authors are grateful to Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Assiut, Egypt for doing the Antibacterial activities tests.

Table I: Characterization data of the newly synthesized compounds.

Compd. No.	M.P. (°C) Yield (%)	Solvent Cryst. (Colour)	Mol. Formula (Mol. Wt)	Elemental analysis calculated / found %		
				C	H	N
2	240 (74)	Dioxan (Yellow)	C ₂₂ H ₂₀ N ₂ O (328)	80.46 80.58	6.14 6.32	8.53 8.51
3	140 (68)	Ethanol (Yellow)	C ₂₄ H ₂₂ N ₂ O ₂ (370.4)	77.82 77.50	5.99 6.23	7.56 7.45
4	295 (73)	Dioxan (Yellow)	C ₂₅ H ₁₆ N ₂ O ₂ (376.4)	79.77 79.52	4.28 4.48	7.44 7.43
5	238 (61)	Ethanol (Yellow)	C ₂₀ H ₁₆ N ₄ O (328)	73.14 73.32	4.91 4.83	17.06 17.22
6	175 (73)	Acetic acid (Yellow)	C ₂₅ H ₁₇ N ₃ O ₂ (391.4)	76.71 76.85	4.38 4.33	10.74 10.68
9	228 (61)	Dioxan (Yellow)	C ₂₈ H ₁₆ N ₄ O ₂ (440.5)	76.34 76.58	3.66 3.68	12.72 12.82
11a	150 (56)	Ethanol (Yellow)	C ₃₁ H ₂₂ N ₄ O ₂ (482.5)	77.16 77.34	4.60 4.53	11.61 11.94
11b	145 (51)	Dioxan (Yellow)	C ₃₂ H ₂₂ N ₄ O ₃ (510.5)	75.28 75.36	4.34 4.11	10.98 11.23
12	310 (71)	Dioxan (Yellow)	C ₃₁ H ₂₃ N ₅ O (481.6)	77.31 77.54	4.81 4.95	14.55 14.86
13	250 (66)	Ethanol (Yellow)	C ₃₀ H ₂₁ N ₅ O (467.5)	77.07 77.23	4.53 4.62	14.98 14.77
15	210 (64)	Ethanol (Yellow)	C ₃₉ H ₂₈ N ₆ O ₂ S (644.7)	72.65 72.77	4.38 4.56	13.04 13.11
18	220 (46)	Ethanol (Yellow)	C ₂₃ H ₁₉ N ₃ O ₂ (369.4)	74.78 74.82	5.18 5.34	11.37 11.68
19	228 (68)	Ethanol (Yellow)	C ₂₂ H ₁₇ N ₃ O ₃ (371.4)	71.14 71.34	4.61 4.68	11.32 11.65
20	132 (58)	Ethanol (Yellow)	C ₂₆ H ₂₃ N ₃ O ₂ (409.5)	76.25 76.43	5.66 5.98	10.26 10.34
21	230 (73)	Dioxan (Yellow)	C ₂₇ H ₁₇ N ₃ O ₂ (415.4)	78.06 78.12	4.13 4.21	10.12 10.32

Table II: Spectral data of the newly synthesized compounds.

Compd. No.	Spectral data: IR (KBr) ν_{\max} (cm ⁻¹), ¹ H NMR δ ppm and Ms: m/z (%)
2	IR ν : 1657 (CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 1.33 (m, 2H, CH ₂ -cyclohexane), 1.40 (m, 2H, CH ₂ -cyclohexane), 1.96 (t, 2H, CH ₂ -cyclohexane), 2.94 (t, 2H, CH ₂ -cyclohexane), 7.15 (s, 1H, ethylene-H), 7.43-7.68 (m, 10H, Ar-H) and 9.34 (s, 1H, pyrazole-H).
3	IR ν : 1673, 1655 (2CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 1.49 (s, 6H, 2CH ₃), 2.21 (s, 4H, 2CH ₂ -cyclohexane), 7.45-7.70 (m, 10H, Ar-H), 7.30 (s, 1H, ethylene-H) and 9.15 (s, 1H, pyrazole-H).
4	IR ν : 1708, 1677 (2CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 7.43-7.76 (m, 14H, Ar-H), 7.26 (s, 1H, ethylene-H) and 9.01 (s, 1H, pyrazole-H). Ms: m/z (%), 376 (M ⁺ , 35.6), 375 (100), 331 (18), 276 (14.6), 215 (13.6), 140 (9.1), 105 (10), 77 (59.5) and 51 (12.5).
5	IR ν : 3118 (NH) and 1670 (CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 2.35 (s, 3H, CH ₃ -pyrazolone), 7.00 (s, 1H, NH), 7.42-7.68 (m, 10H, Ar-H), 7.10 (s, 1H, ethylene-H) and 9.11 (s, 1H, pyrazole-H). Ms: m/z (%), 328 (M ⁺ , 4), 273 (14.7), 247(31.6), 191 (4.8), 105 (33.4), 77(100) and 51(30.7).
6	IR ν : 1790 (CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 7.02 (s, 1H, ethylene-H), 7.42-7.95 (m, 15H, Ar-H) and 9.10 (s, 1H, pyrazole-H).
9	IR ν : 3386 (NH), 2223 (CN), 1722 (CO) and 1679 (CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 7.37-8.00 (m, 14H, Ar-H), 9.05 (s, 1H, pyrazole-H) and 10.07 (s, H, NH).
11a	IR ν : 3350 (OH), 1653 (CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 7.10 (s, 1H, ethylene-H), 7.25-7.97 (m, 19H, Ar-H), 9.40 (s, 1H, pyrazole-H) and 10.01 (s, 1H, OH).
11b	IR ν : 3455-3250 (br. OH), 1670, 1650 (2CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 7.42-8.08 (m, 19H, Ar-H), 7.10 (s, 1H, ethylene-H), 9.11 (s, 1H, pyrazole-H) and 10.10 (s, 1H, OH).
12	IR ν : 3381, 3290 (NH ₂) and 1642 (CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 7.35-8.60 (m, 19H, Ar-H), 7.22 (s, 1H, ethylene-H), 9.25 (s, 1H, pyrazole-H) and 9.99 (s, 2H, NH ₂). Ms: 481 (M ⁺ , 1%), 391(10.1), 258 (21.2), 155 (21.2), 105 (86.9), 77 (100) and 51 (28.8).
13	IR ν : 1655 (CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 7.26-8.53 (m, 19H, Ar-H), 7.11 (s, 1H, ethylene-H) and 9.33 (s, 1H, pyrazole-H). Ms: m/z (%), 467 (M ⁺ , 36.2), 409 (17.6), 347 (45), 305 (57.8), 259 (44.6), 181(35), 105(100), 77 (74.9) and 51 (14.6).
15	IR: 3272 (NH), 2215 (CN) and 1650, 1637 (2CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 2.24 (s, 3H, CH ₃), 2.44 (s, 3H, CH ₃), 7.13-7.98 (m, 19H, Ar-H), 7.11 (s, 1H, ethylene-H), 8.70 (s, 1H, pyrazole-H) and 9.91 (s, 1H, NH).
18	IR ν : 3279 (NH), 1702 (CO) and 1643 (CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 2.05 (s, 3H, COCH ₃), 3.22 (s, 3H, CH ₃ -pyrrolone), 7.32 (s, 1H, ethylene-H), 7.38-8.01 (m, 10H, Ar-H), 8.72 (s, 1H, pyrazole-H), and 10.00 (s, 1H, NH).
19	IR ν : 3281 (NH), 1697, 1641 and 1630 (3CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 2.05 (s, 3H, COCH ₃), 4.01 (s, 1H, CH-methine), 6.39 (s, 1H, ethylene-H), 7.15-7.98 (m, 10H, Ar-H), 9.34 (s, 1H, pyrazole-H) and 10.44 (s, 1H, NH). Ms: m/z (%), 371 (M ⁺ , 100), 329 (47.3), 259 (99.8), 155 (42.2), 104 (51.1), 77 (85.5) and 51 (10.4)
20	IR ν : 3250 (NH), 1670 and 1655 (2CO).
21	IR ν : 3278 (NH), 1715 and 1680 (2CO). ¹ H-NMR (DMSO- <i>d</i> ₆) δ : 7.14 (s, 1H, ethylene-H), 7.42-7.99 (m, 14H, Ar-H), 9.04 (s, 1H, pyrazole-H) and 9.73 (s, 1H, NH).

Table III: The Antibacterial activity of some newly synthesized compounds. (Diameter of inhibition zone in mm)

Comp. No.	Escherichia Coli	Pseudomonas areuginosa	Klebsiella Pneumonia
4	-	25	20
6	9	-	10
11a	9	-	-
11b	-	-	10
12	-	-	20
13	-	-	-
15	11	-	20
18	-	25	10
19	11	20	20
21	9	17	20

No inhibition (-).

References

- 1 M. A. M. GAD-ELKAREEM AND A. O. ABDELHAMID, *Afinidad*, **61**(513), 427 (2004).
- 2 T. I. EL-EMARY, A. KHALIL, G. A. M. EL-HAG ALI AND A. A. A. M. EL-ADASY, *Phosphorus, Sulfur and Silicon and related elements*, **180**, 19, (2005).
- 3 M. E. JUNG, S. J. MIN, K. N. HOUK AND D. ESS, *J. Org. Chem.* **69**(26), 9085, (2004).
- 4 A. ARMSTRONG, L. H. JONES, J. D. KNIGHT AND R. D. KELSEY, *Org. Lett.* **17**; 7(4), 713, (2005).
- 5 T. NORRIS, R. COLON-CRUZ, AND D. H. RIPIN, *Org. Biomol. Chem.* **3**(10), 1844, (2005).
- 6 A. M. HUSSEIN AND T. I. EL-EMARY, *J. Chem. Res. (S)* **1**, 20-21, (1998); M., 0231-0241.
- 7 A. M.R. BERNARDINO, A. O. GOMES, K. S. CHARRET, A. C.C. FREITAS, G. M.C. MACHADO, M. M. CANTO-CAVALHEIRO, L. L. LEON AND V. F. AMARAL, *Eur. J. Med. Chem.* **41**, 80 (2006).
- 8 W. CUNICO, C. A. CECHINEL, H. G. BONACORSO, M. A. P. MARTINS, N. ZANATTA, M. V. N. DE SOUZA, I. O. FREITAS, R. P. P. SOARES AND A. U. KRETTLI, *Bioorg. Med. Chem. Lett.* **16** (3), 649 (2006).

- 9 M. SÜKÜROĞLU, B. C. ERGÜN, S. ÜNLÜ, M. F. SAHİN, E. KÜPELİ, E. YESİLADA, AND E. BANOĞLU, *Arch. Pharm. Res.* **28** (5), 509 (2005).
- 10 S. CHIMICHI, M. BOCCALINI, M. M. M. HASSAN, G. VIOLA, F. DALL'ACQUA AND M. CURINI, *Tetrahedron*, **62**, 90, (2006).
- 11 E. AKBAS, I. BERBER, A. SENER AND B. HASANOV, *IL Farmaco*, **60**, 23 (2005).
- 12 A. TANITAME, Y. OYAMADA, K. OFUJI, H. TERAUCHI, M. KAWASAKI, M. WACHI AND J. YAMAGISHI, *Bioorg. Med. Chem. Lett.* **15** (19), 4299 (2005).
- 13 T. I. EL-EMARY, A. M. KAMAL EL-DEAN AND H. S. EL-KASHEF, *IL Farmaco*, **53**, 383 (1998).
- 14 T. I. EL-EMARY AND E. A. BAKHITE, *Pharmazie* **54** (2), 106 (1999).
- 15 T. I. EL-EMARY, A. M. HUSSEIN AND H. S. EL-KASHEF, *Pharmazie* **55** (5), 356 (2000).
- 16 J. H. LANGE, H. H. VAN STUIVENBERG, W. VEERMAN, H. C. WALSH, B. STORK, H. K. COOLEN, A. C. McCreary, T. J. Adolfs and C. G. Kruse, *Bioorg. Med. Chem. Lett.* **15** (21), 4794 (2005).
- 17 Q. ZHANG, P. MA, W. WANG, R. B. COLE AND G. WANG, *Drug Metab. Dispos.* **33** (4), 508 (2005).
- 18 F. WUST, T. KNISS, M. KRETZSCHMAR AND R. BERGMANN, *Bioorg. Med. Chem. Lett.* **15** (5), 1303 (2005).
- 19 C. D. COX, M. J. BRESLIN, B. J. MARIANO, P. J. COLEMAN, C. A. BUSER, E. S. WALSH, K. HAMILTON, H. E. HUBER, N. E. KOHL, M. TORRENT, Y. YAN, L. C. KUO AND G. D. HARTMAN, *Bioorg. Med. Chem. Lett.* **15**, 2041 (2005).
- 20 H. S. EL-KASHEF, T. I. EL-EMARY, M. GASQUET, P. TIMON-DAVID, J. MALDONALDO AND P. VANELLE, *Pharmazie*, **55**(8), 572 (2000).
- 21 P. RATHELOT, N. AZAS, H. EL-KASHEF, F. DELMAS, C. DI GIORGIO, P. TIMON-DAVID, J. MALDONADO AND P. VANELLE, *Eur. J. Med. Chem.* **37**(8), 671 (2002).
- 22 S. A. LAUFER, G. K. WAGNER, D. A. KOTSCHENREUTHER AND W. ALBRECHT, *J. Med. Chem.*, **46** (15), 3230 (2003).
- 23 J. C. BARROW, P. G. NANTERMET, S. R. STAUFFER, P. L. NGO, M. A. STEINBEISER, S.S. MAO, S. S. CARROLL, C. BAILEY, D. COLUSSI, M. BOSSERMAN, C. BURLEIN, J. J. COOK, G. SITKO, P. R. TILLER, C. M. MILLER-STEIN, M. ROSE, D. R. MCMASTERS, J. P. VACCA, AND H. G. SELNICK, *J. Med. Chem.*, **46** (25), 5294 (2003).
- 24 K. S. ATWAL, P. WANG, W. L. ROGERS, P. SLEPH, H. MONSHIZADEGAN, F. N. FERRARA, S. TRAEGER, D. W. GREEN AND G. J. GROVER, *J. Med. Chem.*, **47**(5), 1081 (2004).

- 25 S. SARAVANAN , P. S. SELVAN , N. GOPAL , J. K. GUPTA , B. DE. ARCH. Pharmazie **338**(10), 488 (2005).
- 26 A. H. ABADI, S. M. ABOU-SERI, D. E. ABDEL-RAHMAN, CH. KLEIN, O. LOZACH AND L. MEIJER, Eur. J. Med. Chem. **41**(3), 296 (2006).
- 27 A. D. BORTHWICK, D. E. DAVIES, P. F. ERTL, A. M. EXALL, T. M. HALEY, G. J. HART, D. L. JACKSON, N. R. PARRY, A. PATIKIS, N. TRIVEDI, G. G. WEINGARTEN, AND J. M. WOOLVEN, J. Med. Chem. **46**(21), 4428 (2003).
- 28 B. M. KENDA, A. C. MATAGNE, P. E. TALAGA, P. M. PASAU, E. DIFFERDING, B. I. LALLEMAND, A. M. FRYCIA, F. G. MOUREAU, H. V. KLITGAARD, M. R. GILLARD, B. FUKS AND P. MICHEL, J. Med. Chem., **47**(3), 530 (2004).
- 29 X. QIAN, G.B. LIANG, D. FENG, M. FISHER, T. CRUMLEY, S. RATTRAY, P. M. DULSKI, A. GURNETT, P. S. LEAVITT, P. A. LIBERATOR, A. S. MISURA, S. SAMARAS, T. TAMAS, D. M. SCHMATZ, M. WYVRATT AND T. BIFTU, Bioorg. Med. Chem. Lett. **16** (10), 2817 (2006).
- 30 S. MAHBOOBI, E. EICHHORN, A. POPP, A. SELLMER, S. ELZ AND U. MLLMANN, Eur. J. Med. Chem. **41**(2), 176 (2006).
- 31 A. MAI, S. MASSA, I. CERBARA, S. VALENTE, R. RAGNO, P. BOTTONI, R. SCATENA, P. LOIDL AND G. BROSCHE, J. Med. Chem., **47**(5), 1098 (2004).
- 32 M. A. A. ELNEAIRY, M. A. M. GAD-ELKAREEM AND A. M. ABDEL-FATTAH, Phosphorous, Sulfur and Silicon, **181**(6), 1451 (2006).
- 33 M. S. A. EL-GABY, A. M. SH. EL-SHARIEF, A. A. ATALLA, AND A. A. A. M. EL-ADASY, Heteroatom. Chem., **16** (3), 218 (2005).
- 34 M. S. A. EL-GABY, A. M. SH. EL-SHARIEF, A. A. ATALLA, AND A. A. A. M. EL-ADASY, Afinidad, **60** (507), 475 (2003).
- 35 M. S. A. EL-GABY, A. M. SH. EL-SHARIEF, A. A. ATALLA, AND A. A. A. M. EL-ADASY, J. Chin. Chem. Soc., **51**(2), 327 (2004).
- 36 M. A. KIRA, M. O. ABDEL-REHMAAN AND K. Z. GADALLA, Tetrahedron Lett. 109 (1969).
- 37 G. E. H. ELGEMEIE, A. H. ELGANDOUR, A. M. ELZANATE AND A. M. HUSSEIN, J. Chem. Research (S), 256 (1997).
- 38 Z. E. KANDEEL, E. A. HAFEZ, M. A. SLEIM, F. M. ABDELATIF AND M. H. ELNAGDI, Heteroatom Chem., **6**(4), 305 (1995).
- 39 L. P. CARROD, F. D. GRADY, Antibiotics and Chemotherapy, 3rd ed.: Churchill Livingstone; Edinburg. 477 (1972).